Korean drug maker Celltrion announced that it has completed enrollment in its phase 3 clinical trial of CT-P17.
Korean drug maker Celltrion announced that it has completed enrollment in its phase 3 clinical trial of CT-P17, a proposed biosimilar adalimumab, in patients with rheumatoid arthritis (RA).
The company said that it completed enrollment for the study ahead of schedule, which will allow it to complete the trial early, with the aim of an expedited product launch.
The drug maker also noted that it has developed its biosimilar to reflect high-concentration formulations of adalimumab, distinguishing the proposed product from other biosimilar adalimumab options on the market. It is also developing the product to be free of citrates, which are used in some biosimilar adalimumab formulations and which can cause discomfort to the patient during injection.
Separately, Celltrion announced that it has been in discussions with the FDA about its proposed subcutaneous formulation of CT-P13 (Inflectra, Remsima), a biosimilar infliximab product. According to a company statement, phase 1 and phase 2 trials for the subcutaneous formulation of the product will be exempted from the product’s clinical program, and only phase 3 trials will be conducted. The company says that this streamlined plan will reduce development costs and potentially facilitate early US launch of the product.
Celltrion says that it will conduct its phase 3 program in the United States in patients with inflammatory bowel disease, which it called the major indication for the US infliximab market.
In addition to making an appealing choice for patients who are satisfied with treatment with intravenous infliximab but who prefer a subcutaneous route of administration, the new formulation of CT-P13, said Celltrion, could compete with brand-name Humira, another subcutaneously administered anti—tumor necrosis factor therapy.
Currently, the subcutaneous formulation of CT-P13 is under review by the European Medicines Agency (EMA). Celltrion expects the EMA’s Committee for Medicinal Products for Human Use to deliver an opinion on the proposed formulation in the second half of 2019.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.